Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions
about
Oral antineoplastic agents: how do we care about adherence?A randomized controlled trial of the feasibility and preliminary efficacy of a texting intervention on medication adherence in adults prescribed oral anti-cancer agents: study protocol.Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia.Dynamic Assessment of Value During High-Cost Cancer Treatment: A Response to American Society of Clinical Oncology and European Society of Medical Oncology.Impact of pharmacy channel on adherence to oral oncolytics.Impact of the healthcare payment system on patient access to oral anticancer drugs: an illustration from the French and United States contexts.Benchmarks for value in cancer care: an analysis of a large commercial population.Population-based assessment of cancer survivors' financial burden and quality of life: a prospective cohort study.Financial toxicity, Part I: a new name for a growing problem.Inpatient care burden due to cancers in Anhui, China: a cross-sectional household survey.American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options.Self-reported financial burden and satisfaction with care among patients with cancer.Adherence, compliance and persistence to oral antineoplastic therapy: a review focused on chemotherapeutic and biologic agents.Utilization patterns for oral oncology medications in a specialty pharmacy cycle management program.Medication adherence to oral cancer therapy: The promising role of the pharmacist.A retrospective study of patients' out-of-pocket costs for granulocyte colony-stimulating factors.A perfect storm: How tumor biology, genomics, and health care delivery patterns collide to create a racial survival disparity in breast cancer and proposed interventions for change.Exploring barriers to the receipt of necessary medical care among cancer survivors under age 65 years.Oral Antineoplastic Agents: Assessing the Delay in Care.The high price of anticancer drugs: origins, implications, barriers, solutions.For Working-Age Cancer Survivors, Medical Debt And Bankruptcy Create Financial Hardships.BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.Persistence to 5-year hormonal breast cancer therapy: a French national population-based study.Do cancer survivors change their prescription drug use for financial reasons? Findings from a nationally representative sample in the United States.Out of pocket, out of sight? An unmeasured component of the burden of cancer.Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update.Out-of-Pocket and Health Care Spending Changes for Patients Using Orally Administered Anticancer Therapy After Adoption of State Parity Laws.Identifying cancer patients who alter care or lifestyle due to treatment-related financial distress.The financial burden and distress of patients with cancer: Understanding and stepping-up action on the financial toxicity of cancer treatment.Financial Burden in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study.Financial Distress, Use of Cost-Coping Strategies, and Adherence to Prescription Medication Among Patients With Cancer.The impact of pharmacist telephone calls after discharge on satisfaction of oncology patients: A randomized controlled study.Adherence to Oral Anticancer Medications: Evolving Interprofessional Roles and Pharmacist Workforce Considerations.Financial toxicity and implications for cancer care in the era of molecular and immune therapies.Trends in Antineoplastic Receipt after Medicare Payment Reform: Implications for Future Oncology Payment Design
P2860
Q28082909-E78F9FBB-014C-4B96-A40B-6AA7F7082E65Q30692113-AA0D9D43-095E-4E48-B5A4-F17CEE4C47D2Q33756387-76E6F661-7A52-4D8B-9EC1-85174C84A0CEQ33756769-5A0526D0-A502-4E90-93B3-7CED90B2AE2AQ33815415-4EF9A0DC-0756-44E4-959B-5FCA274FC4C5Q33847820-55A603C5-0FA5-4163-9E30-681D6F985EE9Q35205672-611A7F70-8010-4394-9753-B86FC191F51DQ35210611-F4578B35-8DA3-4841-9666-B29DD3D5496FQ35913404-F6B9B7D5-014E-43F4-A71B-6C5902165FAEQ35986373-D803019E-1310-4084-B6E4-ED1CAE3BCADCQ37240851-3B417F1B-80FC-4D86-A043-2C402737299FQ37698221-666442F7-7F35-4EB7-919B-8B65972D86B3Q37965653-D98097BE-A691-44E4-8897-0563250DF87BQ38258719-8E190421-835C-41BC-A008-A2EA1BF84780Q38266160-079C8F39-31B3-488C-BEF5-765BF45A8865Q38427936-51DABE83-0DF4-40C9-BF4D-D65E3D472B7EQ38470766-03E21181-0D36-48E7-AE4E-5D32D5F2BE36Q38602628-5D989687-AF28-4D35-81F6-7BD9F6A51AF3Q38647171-B327244F-E917-4787-AD29-CE0D2609C4BEQ38909657-453ECAF3-5CC8-4B86-95F6-F8BEC976122CQ38924370-6D2C7AFA-F3F9-45B9-9A7E-1E1CBC7FCD17Q39350678-AF5D6BAA-B03C-4DD7-BF9C-824941F4A268Q39419032-89B7B6D4-395D-4695-98E4-D463497637B7Q40327176-0AF26187-4590-4055-AF5A-824615230CBFQ43210863-4CABDF1F-876E-44D6-A318-62358A79DE20Q46580935-40B50003-D7D7-4F9B-AF34-3625D0968A68Q47221850-284A699B-BFCA-4118-B8F6-62A9B61252B0Q48078636-6F97CA61-6B42-477B-BD35-DF87A8350032Q48234920-F6D34827-0160-44F3-B44F-F9E201D484CDQ48504152-217F9150-8EF1-4BFD-95C6-2912E62B5805Q50069903-3A6DDDD3-4CA1-4E3E-BE0F-0C16C9AC0DE4Q50643834-B0457C2F-2FB8-4EC8-84FF-F2082AC90C9CQ54940867-74BADE87-1793-49BB-AF09-018ED183E476Q55265302-21552717-E35E-4AE5-9856-878F91A9C498Q57822900-FB9C1772-6C06-477C-8EA8-07970F79EA5F
P2860
Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions
@ast
Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions
@en
Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions
@nl
type
label
Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions
@ast
Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions
@en
Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions
@nl
prefLabel
Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions
@ast
Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions
@en
Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions
@nl
P2093
P2860
P356
P1476
Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions
@en
P2093
Lee Schwartzberg
Michael Johnsrud
Nadia Husain
Sonya Blesser Streeter
P2860
P304
P356
10.1200/JOP.2011.000316
P407
P433
P577
2011-05-01T00:00:00Z